Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Paul A. Richardson et al.|The Lancet HIV|2023Cited by 14
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083Meredith E. Clement, Richard Novák, Brett Hanscom et al.|Clinical Infectious Diseases|2024Cited by 0
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialAdeola Adeyeye, Zhe Wang, Beatriz Grinsztejn et al.|UNC Libraries|2025Cited by 0